GLI1+ perivascular, renal, progenitor cells: The likely source of spontaneous neoplasia that created the AGMK1-9T7 cell line.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
05
2023
accepted:
11
10
2023
medline:
7
12
2023
pubmed:
7
12
2023
entrez:
7
12
2023
Statut:
epublish
Résumé
The AGMK1-9T7 cell line has been used to study neoplasia in tissue culture. By passage in cell culture, these cells evolved to become tumorigenic and metastatic in immunodeficient mice at passage 40. Of the 20 x 106 kidney cells originally plated, less than 2% formed the colonies that evolved to create this cell line. These cells could be the progeny of some type of kidney progenitor cells. To characterize these cells, we documented their renal lineage by their expression of PAX-2 and MIOX, detected by indirect immunofluorescence. These cells assessed by flow-cytometry expressed high levels of CD44, CD73, CD105, Sca-1, and GLI1 across all passages tested; these markers have been reported to be expressed by renal progenitor cells. The expression of GLI1 was confirmed by immunofluorescence and western blot analysis. Cells from passages 13 to 23 possessed the ability to differentiate into adipocytes, osteoblasts, and chondrocytes; after passage 23, their ability to form these cell types was lost. These data indicate that the cells that formed the AGMK1-9T7 cell line were GLI1+ perivascular, kidney, progenitor cells.
Identifiants
pubmed: 38060571
doi: 10.1371/journal.pone.0293406
pii: PONE-D-23-16019
pmc: PMC10703308
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0293406Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
DMR has stock and other ownership interests in Interpares Biomedicine, Inc, has served in a consultant and advisory role for Pharmazam LLC, has received research funding from Novo Nordisk, Inc and has intellectual property related to the detection of liver cancer. “This does not alter our adherence to PLOS ONE policies on sharing data and materials".
Références
PLoS One. 2010 Dec 22;5(12):e14416
pubmed: 21203544
J Pathol Clin Res. 2018 Jan 17;4(1):3-18
pubmed: 29416873
Carcinogenesis. 2006 Feb;27(2):350-9
pubmed: 16280331
Cell Stem Cell. 2015 Jan 8;16(1):3-4
pubmed: 25575074
Vaccine. 2017 Oct 4;35(41):5503-5509
pubmed: 28434690
Br J Cancer. 1947 Dec;1(4):379-82
pubmed: 18906315
Stem Cell Res Ther. 2021 Mar 20;12(1):197
pubmed: 33743826
J Exp Med. 1957 Jul 1;106(1):145-58
pubmed: 13439121
PLoS One. 2022 Oct 24;17(10):e0275394
pubmed: 36279283
Vaccine. 2014 Aug 20;32(37):4799-805
pubmed: 25024114
Ann Ist Super Sanita. 2007;43(2):144-55
pubmed: 17634663
Cytotherapy. 2013 Dec;15(12):1527-40
pubmed: 23992827
Clin Chem. 2014 May;60(5):747-57
pubmed: 24486646
Sci Rep. 2020 Mar 25;10(1):5379
pubmed: 32214151
Sci Rep. 2020 Aug 14;10(1):13640
pubmed: 32796873
Dev Cell. 2004 Apr;6(4):483-95
pubmed: 15068789
J Cell Biol. 1963 May;17:299-313
pubmed: 13985244
Kidney Int. 2018 Aug;94(2):259-267
pubmed: 29685496
Biochem Pharmacol. 2007 Jan 1;73(1):1-14
pubmed: 16904651
BMC Cancer. 2020 Apr 3;20(1):272
pubmed: 32245446
Am J Pathol. 2006 Feb;168(2):706-13
pubmed: 16436683
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16616-21
pubmed: 19805346
Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6619-23
pubmed: 8022827
Exp Ther Med. 2017 Jan;13(1):280-284
pubmed: 28123502
Nature. 1970 Jul 11;227(5254):168-70
pubmed: 4316953
Cell Stem Cell. 2015 Jan 8;16(1):51-66
pubmed: 25465115
Biologicals. 2008 Jan;36(1):65-72
pubmed: 17933552
Cancer Res. 1954 Jun;14(5):327-39
pubmed: 13160960
Cell Cycle. 2009 May 1;8(9):1338-43
pubmed: 19342894
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
Front Cell Neurosci. 2019 Jun 28;13:282
pubmed: 31316352
Cell Stem Cell. 2017 Mar 2;20(3):345-359.e5
pubmed: 28111199
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):503-8
pubmed: 15623552